|Description||CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with no CNS side effects.|
|Solubility||Soluble in DMSO|
|Storage||Store at -20 °C|
|Application||Potent, orally active CB1/CB2 receptor agonist with limited brain penetration|
|Quality Standard||Enterprise standard|
|Shelf Life||As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.|
Rimonabant is a selective antagonist of CB1 with IC50 of 13.6 nM and EC50 of 17.3 nM in hCB1 transfected HEK 293 membrane.
Leelamine, a diterpene molecule, has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Leelamine is also a PDK(p...
Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist(Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively).
AM-1220 is a selective cannabinoid receptor CB1 agonist , with about 19x selectivity for CB1 over the related CB2 receptor originated by Sterling Winthrop. In O...
ACEA is a selective cannabinoid receptor 1 (CB1R) agonist (Ki = 1.4 nM) with much higher affinity over CB2R. CB1 receptors are mainly expressed in the central a...
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...
Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased ...
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
CB-13 is a dual agonist of the CB1 (IC50 = 15 nM) and CB2 (IC50 = 98 nM) receptors, displays antihyperalgesic activity in a rat model of neuropathic pain with n...
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
AM 1714, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor.
GSK-554418A is a azaindole Cannabinoid receptor type 2 (CB2) agonist. It can be used for the treatment of chronic pain.
WIN 55212-2 mesylate
The mesylate salt form of WIN 55212-2, an aminoalkylindole derivative, is a CB receptor agonist and could be effective against some inflammatory reponse. IC50: ...
AM1248 is an adamantoylindole derivative acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2.
Ibipinabant is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2), respectively.
Taranabant is a cannabinoid 1 receptor inverse agonist ( IC50 =0.3 nM).
Otenabant HCl is a selective and high affinity antagonist of CB1 with Ki value of 0.7 nM.
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...
A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM ove...